Testing a prostate cancer drug for bioequivalence
Part of Cancer, Kidney & urinary clinical trials.
This trial checks if a new version of the prostate cancer drug triprerelin works the same as the current one. It may be an option for men with prostate cancer who need hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older with prostate cancer confirmed by biopsy.
- Your doctor has recommended hormone therapy, and you have not had hormone therapy before, or you are currently stable on triprerelin, or you have had it before and can take it again.
- You weigh at least 110 pounds (50 kg) and your body mass index (BMI) is between 19 and 30.
- You are in generally good health with adequate blood, liver, and kidney function.
- You agree to use effective birth control or no sex for 6 months after the study ends.
- You do not have certain health problems like severe heart disease, uncontrolled diabetes, or a history of serious allergic reactions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug, alone or with other treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if it can shrink tumors or slow the disease.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
This study tests a new oral tablet (HRS-7525) for men with advanced prostate cancer that has spread. It aims to see if the drug is safe and effective, and may offer a new treatment option for those who have not responded to standard therapies.
This Phase 3 trial compares two treatment approaches: stereotactic radiation therapy by itself versus the same radiation plus hormone therapy (ADT). It aims to see which plan works better for men with higher-risk prostate cancer without spread to lymph nodes or distant sites.
Hear when a new Prostate Cancer (CRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.